

Filed by Berkeley Lights, Inc.  
Pursuant to Rule 425 of the Securities Act of 1933  
and deemed filed pursuant to Rule 14a-12  
of the Securities Exchange Act of 1934  
Subject Company: IsoPlexis Corporation  
Commission File No.: 001-40894  
Date: December 22, 2022


The following is a presentation made to the employees of Berkeley Lights, Inc. (“Berkeley Lights”) by Berkeley Lights management on December 22, 2022:

---

# Berkeley Lights Town Hall

December 22, 2022

Strictly Private & Confidential



# Forward-Looking Statements

Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for completing the transaction, benefits and synergies of the transaction, future opportunities for the combined company and products and any other statements regarding Berkeley Lights' and IsoPlexis' future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are "forward-looking" statements made within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "may," "believe," "anticipate," "would," "could," "should," "intend," "seek," "plan," "will," "expect(s)," "estimate(s)," "forecast(s)," "project(s)," "target(s)," "forecast(s)," "contemplate(s)," "positioned," "potential," "strategy," "outlook," "forward," "continuing," "ongoing" and similar expressions. All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the statements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking statements are the following: the risk that the proposed transaction may not be completed in a timely manner or at all; the failure to receive, on a timely basis or otherwise, the required approvals of the proposed transaction by both Berkeley Lights' stockholders and IsoPlexis' stockholders; the possibility that any or all of the various conditions to the consummation of the proposed transaction may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the proposed transaction, including in circumstances which would require Berkeley Lights or IsoPlexis to pay a termination fee; the effect of the announcement, pendency or completion of the proposed transaction on each of Berkeley Lights' and IsoPlexis' ability to attract, motivate or retain key employees, its ability to maintain relationships with its customers, suppliers, distributors and others with whom it does business, or its operating results and business generally; risks related to the proposed transaction diverting management's attention from each of Berkeley Lights' and IsoPlexis' ongoing business operations; the risk of stockholder litigation in connection with the proposed transaction, including resulting expense or delay; the possibility that the parties may be unable to achieve expected synergies and operating efficiencies in connection with the proposed transaction within the expected timeframes or at all and to successfully integrate IsoPlexis' operations into those of Berkeley Lights; the integration of IsoPlexis' operations into those of Berkeley Lights being more difficult, time-consuming or costly than expected; effects relating to the announcement of the proposed transaction or any further announcements or the consummation of the proposed transaction on the market price of the common stock of each of Berkeley Lights and IsoPlexis; the possibility that each of Berkeley Lights' and IsoPlexis' expectations as to expenses, cash usage and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; the impacts of changes in general economic and business conditions, including changes in the financial markets; the implementation of each of Berkeley Lights' and IsoPlexis' business model and strategic plans for its products and technologies, and challenges inherent in developing, manufacturing, launching, marketing and selling existing and new products; uncertainties in contractual relationships, including interruptions or delays in the supply of components or materials for, or manufacturing of, products for each of Berkeley Lights and IsoPlexis; the ability of each of Berkeley Lights and IsoPlexis to establish and maintain intellectual property protection for products or avoid or defend claims of infringement; risks relating to competition within the industry in which each of Berkeley Lights and IsoPlexis operate; the impacts of potential product performance and quality issues; changes to and the impact of the laws, rules and regulations that regulate each of Berkeley Lights' and IsoPlexis' operations; and any other risks discussed in each of Berkeley Lights' and IsoPlexis' filings with the SEC, including Berkeley Lights' and IsoPlexis' Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Berkeley Lights and IsoPlexis assume no obligation to update or revise publicly the information in this communication, whether as a result of new information, future events or otherwise, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

## Participants in the Solicitation

Berkeley Lights, IsoPlexis and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction between Berkeley Lights and IsoPlexis under the rules of the SEC. Information regarding Berkeley Lights' directors and executive officers is set forth in Berkeley Lights' Proxy Statement on Schedule 14A for its 2022 Annual Meeting of Stockholders, which was filed with the SEC on April 15, 2022, and in certain of Berkeley Lights' Current Reports on Form 8-K. To the extent holdings of Berkeley Lights' securities by Berkeley Lights' directors and executive officers have changed since the amounts set forth in such proxy statement, such changes have been or will be reflected on subsequent statements of beneficial ownership filed with the SEC. Information regarding IsoPlexis' directors and executive officers is set forth in IsoPlexis' revised Proxy Statement on Schedule 14A for its 2022 Annual Meeting of Stockholders, which was filed with the SEC on April 29, 2022, and in certain of IsoPlexis' Current Reports on Form 8-K. To the extent holdings of IsoPlexis' securities by IsoPlexis' directors and executive officers have changed since the amounts set forth in such proxy statement, such changes have been or will be reflected on subsequent statements of beneficial ownership filed with the SEC. These documents can be obtained free of charge from the sources indicated below. Additional information regarding the interests of these participants will be set forth in the joint proxy statement/prospectus relating to the proposed transaction when it becomes available.

## Additional Information and Where to Find It

In connection with the proposed transaction between Berkeley Lights and IsoPlexis, Berkeley Lights and IsoPlexis intend to file relevant materials with the SEC, including a Berkeley Lights registration statement on Form S-4 that will include a joint proxy statement of Berkeley Lights and IsoPlexis that also constitutes a prospectus of Berkeley Lights. **INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT BERKELEY LIGHTS, ISOPLEXIS AND THE PROPOSED TRANSACTION.** The joint proxy statement/prospectus and other documents relating to the proposed transaction (when they are available) can be obtained free of charge from the SEC's website at [www.sec.gov](http://www.sec.gov). These documents (when they are available) can also be obtained free of charge from Berkeley Lights' investor relations website at [www.investors.berkeleylights.com](http://www.investors.berkeleylights.com) or from IsoPlexis' investor relations website at [www.investors.isoplexis.com](http://www.investors.isoplexis.com).

## No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

# A Transformational Combination



LIVE CELL, FUNCTIONAL BIOLOGY

Most comprehensive technology portfolio to isolate, manipulate, and characterize live cells



DEEP PROFILING OF SINGLE CELLS

The only single-cell platform enabling functional proteomics

New, Combined Company Name:

# PhenomeX

(Nasdaq: CELL)

A FUNCTIONAL CELL BIOLOGY COMPANY

# PhenomeX: The Functional Cell Biology Company

## WHAT WE DO

Enable scientists to unlock the potential of cell biology for research and clinical applications

## HOW WE DO IT

By providing a deeper analysis of cell function while preserving the live cells of interest

## WHY IT MATTERS

Because understanding the phenome is central to all questions in biology

Provides live cell biology research tools and services that deliver deep insights into cellular function and gain new perspectives on phenomes



# IsoPlexis at a Glance



Accelerating the fight against our toughest diseases by revealing the true functional biology of every patient cell via proteomics and transcriptomics

277 instruments in the field


116 publications

\$18.9M TTM revenue

LEADING CUSTOMER BASE  
in Pharma, Biotech, Medical Centers


- 100% of top 15 pharma<sup>(1)</sup>
- 81% of comprehensive cancer centers<sup>(2)</sup>

## Highly Multiplexed Proteomic Barcoding



## Rapidly Growing Installed Base

Installed Base (Total Instruments)



(1): By 2020 revenue.

(2): Based on the National Cancer Institute's list of Comprehensive Cancer Centers.

# Accelerates Progress Across Every Pillar of Berkeley Lights' Strategic Plan

Building a world-class team

- ✓ Led by Berkeley Lights' experienced Board of Directors
- ✓ Enhances a proven management team highly experienced in company integration and consolidating organizations

Prioritizing R&D return on investment

- ✓ Unites complementary portfolios that will extend its leadership through the entire functional cell biology continuum with highly differentiated technology
- ✓ Accelerating innovation by:
  - Focusing resources on the highest-return initiatives
  - Using the lower-cost IsoPlexis platform to offer enhanced functionality from Berkeley Lights' technology portfolio
  - Sustaining competitive advantage through a formidable intellectual property estate of more than 600 issued patents

Delivering consistent commercial execution

- ✓ Diversifies customer base, uniting positions in biopharma & academic segments
- ✓ Expands product portfolio offering with increased accessibility to meet customers' workflow needs
- ✓ Strengthens global reach with a 75% increase in the size of the sales organization
- ✓ Enhances the focus on recurring revenue

# Accelerates Progress Across Every Pillar of Berkeley Lights' Strategic Plan

Creating a platform for further consolidation in high-growth cell biology tools

- ✓ Participating in a larger cell biology market with a wide range of tools and services through cross-selling opportunities to existing and new customers
- ✓ Enabling significant productivity through combined R&D, G&A and supply chain / manufacturing infrastructure
- ✓ Evaluating M&A opportunities that will further accelerate profitable growth and leverage a combined cost structure

Generating positive operating cash flow by 2024

- ✓ Anticipated cost synergies of approximately \$70 million annualized by 2024
- ✓ Expected positive operating cash flow generation at \$150 million in revenue by 2024, earlier than Berkeley Lights expected to as a standalone company




# Confidentiality Reminder

- ISO and BLI are still operating independently
- All work associated with diligence and integration is CONFIDENTIAL
- Due diligence materials and work shall not be shared outside of BLI's due diligence team
- Integration planning work shall not be shared outside of the integration planning team
- BLI's integration leader (Eric Hobbs) will coordinate communications to both organizations as needed throughout the process




# PhenomeX

A FUNCTIONAL  
CELL BIOLOGY  
COMPANY



PhenomeX

Find and activate cell functionality that can improve human life.  
See beyond the surface at [PhenomeX.com](https://PhenomeX.com)



PhenomeX

Find and activate cell functionality that can improve human life.  
See beyond the surface at [PhenomeX.com](https://PhenomeX.com)

# Q&A Session

Strictly Private & Confidential

